Show simple item record

Primary versus radiation-associated craniofacial osteosarcoma

dc.contributor.authorMcHugh, Jonathan B.en_US
dc.contributor.authorThomas, Dafydd G.en_US
dc.contributor.authorHerman, Joseph M.en_US
dc.contributor.authorRay, Michael E.en_US
dc.contributor.authorBaker, Laurence H.en_US
dc.contributor.authorAdsay, N. Volkanen_US
dc.contributor.authorRabah, Raja M.en_US
dc.contributor.authorLucas, David R.en_US
dc.date.accessioned2007-09-18T19:18:12Z
dc.date.available2007-09-18T19:18:12Z
dc.date.issued2006-08-01en_US
dc.identifier.citationMcHugh, Jonathan B.; Thomas, Dafydd G.; Herman, Joseph M.; Ray, Michael E.; Baker, Laurence H.; Adsay, N. Volkan; Rabah, Raja; Lucas, David R. (2006). "Primary versus radiation-associated craniofacial osteosarcoma." Cancer 107(3): 554-562. <http://hdl.handle.net/2027.42/55776>en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/55776
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16795069&dopt=citationen_US
dc.description.abstractBACKGROUND. Craniofacial osteosarcoma differs from long bone osteosarcoma in that patients are older, tumors are often low grade, and prognosis is more favorable. Although most are sporadic, some tumors occur in association with prior radiation therapy. The purpose of the current study was to compare clinicopathologic and prognostic features of primary and radiation-associated osteosarcoma. METHODS. The study group consisted of 15 primary and 6 radiation-associated osteosarcomas. Clinical and follow-up data were obtained in every case. Tissue microarrays were immunohistochemically stained for p53, pRB, Ki-67 (MIB-1), and ezrin. DNA was sequenced for TP53 mutations. RESULTS. All radiation-associated osteosarcomas were high grade and half were fibroblastic. In contrast, 47% of primary craniofacial osteosarcomas were high grade and only 1 was fibroblastic. All radiation-associated osteosarcomas recurred, half the patients died of disease, 2 were alive with unresectable tumors, whereas only 1 was alive without disease. In contrast, 80% of patients with primary tumors were alive without disease, 33% had local recurrences, and 13% died of disease. Radiation-associated tumors overexpressed p53 more often (33% vs. 13%), more often had TP53 mutations (33% vs. 8%), had higher proliferative activity (67% vs. 0% showing >50% MIB-1 staining), and expressed ezrin more frequently (83% vs. 40%) than primary tumors. Compared with a control group of 24 high- and 7 low-grade primary extremity osteosarcomas, radiation-associated tumors marked as the high-grade tumors. CONCLUSIONS. Craniofacial radiation-associated osteosarcomas are high-grade tumors that behave more aggressively than most primary craniofacial osteosarcomas. In addition, they demonstrate higher expression rates of adverse prognostic indicators, further highlighting the distinction. Cancer 2006. © 2006 American Cancer Society.en_US
dc.format.extent353816 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherCancer Research, Oncology and Pathologyen_US
dc.titlePrimary versus radiation-associated craniofacial osteosarcomaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan ; Department of Pharmacology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 763-4095 ; Department of Pathology, University of Michigan, 1500 E. Medical Center Dr., Room 2G332 UH, Ann Arbor MI, 48109-0054en_US
dc.contributor.affiliationotherDepartment of Pathology, Wayne State University, Detroit, Michiganen_US
dc.contributor.affiliationotherDepartment of Pathology, Wayne State University, Detroit, Michiganen_US
dc.identifier.pmid16795069en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/55776/1/22019_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/cncr.22019en_US
dc.identifier.sourceCanceren_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.